Drug intelligence / Profile preview

PRJ212

Development stage: Unknown
Lead developer: Oryzon Genomics
Administration: Oral

Overview

PRJ212 is an investigational porcine brain-derived nutritional compound developed as a medical food by Bioiberica in collaboration with Fundació ACE (Institut Català de Neurociències Aplicades). It contains a mixture of characterized bioactive principles that exert neuroprotective effects. Preclinical studies have demonstrated that PRJ212 helps preserve neuronal architecture and cognitive function by providing resistance against amyloid-beta-induced neurotoxicity. It has been evaluated in clinical trials for its potential to improve memory and mitigate cognitive decline in patients with mild severity Alzheimer's disease.

Beyond the preview

Go deeper on PRJ212.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRJ212.

Explore the full profile